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Purpose: To compare safety and efficacy of vascular plugs (VPs) and fibered platinum coils (FPCs) for embolization in pelvic
congestion syndrome (PCS).
Materials and Methods: A randomized, prospective, single-center study enrolled 100 women with PCS from January 2014
to January 2015. Patients were randomly assigned to 2 groups, and embolization was performed with FPCs (n ¼ 50) or VPs
(n ¼ 50). Mean age of patients was 42.7 years ± 7.60, and mean visual analog scale (VAS) score for pelvic pain before
treatment was 7.4 ± 7.60. Primary outcome (clinical success at 1 y using a VAS), number of devices, procedure and fluo-
roscopy times, radiation doses, costs, and complications were compared, and participants were followed at 1, 3, 6, and 12
months.
Results: Clinical success and subjective improvement were not significantly different at 1-year follow-up (89.7% for FPCs vs 90.6%
for VPs; P ¼ .760). Mean number of devices per case was 18.2 ± 1.33 for FPCs and 4.1 ± 0.31 for VPs (P < .001). Three FPCs and 1
VP migrated to pulmonary vasculature approximately 3–6 months after the embolization procedure; all were retrieved without com-
plications. The FPC group had a significantly longer fluoroscopy time (33.4 min ± 4.68 vs 19.5 min ± 6.14) and larger radiation dose
(air kerma 948.0 mGy ± 248.45 vs 320.7 mGy ± 134.33) (all P < .001).
Conclusions: Embolization for PCS resulted in pain relief in 90% of patients; clinical success was not affected by embolic device. VPs
were associated with decreased fluoroscopy time and radiation dose.
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j.jvir.2017.09.011Pelvic congestion syndrome (PCS) usually manifests as a
dull chronic pain in the lower abdomen that can be inten-
sified by the Valsalva maneuver or standing in the upright
position owing to pelvic venous incompetence. The pa-
thology is poorly understood and may result from pelvic
valvular insufficiency and altered vein walls secondary to
multiple pregnancies or high estrogen levels, leading to
incompetent veins, blood stasis, and retrograde blood flow
in the pelvic vasculature (1,2). At the present time, the
treatment of choice for pelvic varicose veins is sclero-
therapy followed by embolization with coils, or just coil
embolization (3–8). The embolization procedure is a sim-
ple technique with a success rate of 98%–100% in all cases
EDITOR’S RESEARCH HIGHLIGHTS
 Embolization for treatment of pelvic congestion
syndrome is effective, resulting in pain relief in 90%
of patients, with durable symptom relief at 1 year.
 Should patient symptoms persist for 30 days after
initial embolization, consider repeat imaging to
evaluate for persistent or recurrent varices that may
require additional embolization.
 Embolization device, either plugs or coils, did not
impact clinical outcomes after embolization for PCS.
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with improvement achieved in 80%–93% at 1–5 years of
follow-up (5–7). Recurrence is rare, but some authors have
reported recurrence rates of 5%–42% in patients treated
with embolization (3–7,9,10). Despite the excellent pub-
lished results, the most important disadvantages of this
treatment are the possibility of coil migration and the
extensive procedure time and irradiation dose received in
the pelvic area (7,11).
Vascular plugs (VPs) are well-established embolic devices
that can be an excellent alternative to coils for embolization
of medium-sized to large-sized arterial or venous vessels
(12). Multiple clinical applications have been described
since the introduction of VPs in 2004, but randomized
studies have been performed only to compare arterial
embolization or variceal embolization after transjugular
intrahepatic portosystemic shunt procedures (13–15). There
are fewer publications related to the use of VPs in peripheral
venous embolization. Among recent studies, only 2 have
used VPs to treat PCS (16,17), but no randomized studies
exist. Lopez (18) suggested embolization of pelvic venous
plexus to treat the entire vessel, including the larger truncal
draining tributaries to prevent new collateralization, which
would increase the number of devices used. This prospective
randomized study compared the safety and efficacy of 2
embolic agents for treating PCS: fibered platinum coils
(FPCs) and VPs. This randomized controlled trial was per-
formed to test the hypothesis that venous embolization for
PCS with VPs could reduce the number of embolic devices
and procedure time without significant differences in the
clinical success or complication rate compared with embo-
lization performed with FPCs.MATERIALS AND METHODS
Study Design
This randomized controlled parallel trial was approved by
the regional and institutional review board (reference
number PI14/000164), registered at ClinicalTrials.gov
(NCT02796092), and conducted in accordance with the
principles of the Declaration of Helsinki. Written informed
consent was obtained from all participants for both the
procedure and the study. Eligible patients were randomly
assigned to 2 groups following block randomization(4 patients in each block) for treatment with either FPCs or
VPs at a 1:1 ratio (Figs 1, 2). All patients were recruited
from January 2014 to January 2015. The primary
outcome was clinical success as subjectively assessed by
the patients. Secondary outcomes were complications,
need for re-embolization secondary to lack of improve-
ment, recurrence of initial symptoms or transvaginal
Doppler ultrasound revealing venous reflux or venous
diameter > 6 mm, procedure time, fluoroscopy time,
radiation dose, and cost.Study Population and Eligibility
The study was carried out in a single center. All patients
were referred from a vascular surgeon, underwent trans-
vaginal Doppler ultrasound to diagnose PCS and pelvic
varices, and met the eligibility criteria (Table 1). Diagnosis
of PCS involved a combination of symptoms and ultrasound
findings (Fig 2). Baseline patient data are presented in
Table 2.Randomization and Blinding
Patients were enrolled in the study by a vascular surgeon
who referred the patients to the interventional vascular unit.
The team epidemiologist generated a random allocation
sequence using Research Randomizer Version 4.0 (19), and
the research nurse assigned eligible patients to the FPC or
VP group. All patients were blinded to the device used. The
performing radiologists were not blinded, but the interven-
tional radiologists performing the clinical follow-up were
blinded to group allocation.Sample Size
Assuming that both methods were equally effective based
on the experience of the research group and the literature
(13), the primary outcome (ie, clinical success) was not used
to calculate the sample size. Instead, sample size was
determined by computer software (G*Power 3.1; Universit€at
Kiel, Kiel, Germany) using retrospective data from patients
seen in 2013 (7), comparing the mean total procedure time
for both methods (41.2 min ± 4.66 vs 35.0 min ± 4.43). To
detect the above-mentioned differences with an a error of
.05 and 80% power using a 2-sided test, 10 patients in each
group was considered enough. As the annual volume
of referral of patients with PCS to the interventional vascular
unit was higher, it was decided to include 50 patients in
each group.Baseline Data
Mean patient age was 42.7 years ± 7.60 (range, 29–60 y).
Patients had a mean of 1.85 children ± 0.88 and reported an
initial mean visual analog scale (VAS) score of 7.4 ± 1.34.
The patients receiving VPs were older (44.3 y ± 8.45 vs
41.0 y ± 6.26; P ¼ .004) and had worse pain (VAS median
score 7.00 vs. 8.00; P ¼ .004). No other baseline factors
were significantly different between the 2 groups (Table 2).
Figure 1. Consolidated Standards of Reporting Trials flow diagram.
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2017 3Technique
The same team (interventional radiologist [M.A.D.G.] and
assistant nurse, both with > 30 years of experience in the
field) performed all embolization procedures. The same
angiography catheterization laboratory with an Allura Xper
Philips FD20 (Philips Medical Systems Nederland BV, Best,
Netherlands) was used. All procedures were carried out with
a low fluoroscopy pulse rate (15 pulses/s, 10-ms pulse) with
a 0.9-mm copper and 1-mm aluminum filters. A 48-cm field
of view, which presented a total radiation dose of 24
μGy/min in a methacrylate phantom of 20 cm; 3 frames/s
was chosen for pelvic or abdominal digital subtraction
angiography studies. The preferred vascular access was the
right internal jugular vein or the left if it was not accessible
(n ¼ 3 patients). A 10-cm, 6-F introducer sheath (Radifocus;
Terumo Europe, Leuven, Belgium) was used for the FPC
procedures, and a 90-cm, 7-F introducer sheath (Flexor
Raabe Guiding Sheath; Cook Medical, Bjaeverskov,
Denmark) was used for the VP procedures. A C2, MPA, or
SIM2 catheters (Impress Peripheral Angiographic Catheters;
Merit Medical, South Jordan Utah) over a hydrophilic guide
wire was used to target the ovarian and internal iliac veins.
Embolization was started in the right ovarian vein, followed
by the left ovarian vein, and finishing with the internal iliac
veins (right and left). Embolization of all venous plexuses
was performed at the lower aspect of the veins where all
collateral veins converge to avoid occlusion of the deep
pelvic plexus. In the FPC group, several 0.035-inch Nester
coils (Cook Medical) of different sizes (8–20 mm in diam-
eter, 7 or 14 cm in length) were used until complete oc-
clusion of the 4 targeted veins was achieved. The unit price
was 162.0V. In the VP group, an 8- to 22-mm AmplatzerVascular Plug II (St. Jude Medical, St Paul, Minnesota) was
used, with a unit price of 880.0V. All the devices were
oversized depending on the targeted vessel and the experi-
ence of the interventional radiologist (7); it was oversized
approximately 1–2 mm in all targeted vein axes, corre-
sponding to an oversize of 20%–35% in ovarian veins and
15%–20% in internal iliac veins. Occlusion was confirmed
venography performed after embolization. During the
intervention, the following data were collected by the data
manager (V.M.) in an SPSS database (IBM SPSS Version
21.0; IBM Corp, Armonk, New York): number of devices
deployed, occluded venous axis (left ovarian, right ovarian,
left internal iliac, or right internal iliac), intervention time,
fluoroscopy time, radiation dose (dose-area product [DAP]
and air kerma), and any complication during the interven-
tion. All patients were discharged 4 hours after the embo-
lization procedure. No intravascular sclerotherapy or opioids
for postoperative analgesia were administered.
Outcomes
Clinical success was defined as the relief of symptoms
occurring before the procedure, including dyspareunia,
dysmenorrhea, and urinary urgency (assessed by direct ques-
tioning before the procedure and at 1, 3, 6, and 12months) and
subjective pain assessed by a VAS scored from 0 (no pain) to
10 (worst pain possible). Two categorieswere created: relief of
symptoms (VAS score decrease  4 points) and no improve-
ment or worsening (new symptoms, increase or no change in
VAS score, or improvement of VAS score < 3 points) (7).
Secondary endpoints were technical success (feasibility of
embolization of the 4 targeted veins), number of devices used,
total procedure time from venous puncture to venous
Figure 2. Diagnostic methodology.
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total air kerma recorded by the fluoroscopy equipment),
overall complications, and need for re-embolization (sched-
uled during the subsequent 12 months).
Follow-up
Patients in both groups had clinical follow-up at 1, 3, 6, and 12
months after the embolization procedure. Clinical successwas defined as improvement or disappearance of the symp-
toms. VAS score range was 0–10, defining 0 as no pain and 10
as worst pain possible. Related symptoms were recorded and
subjective pain was assessed by the patients at each follow-up
consultation. When no improvement was observed, initial
symptoms recurred, or transvaginal Doppler ultrasound
showed venous reflux or persistence of > 6 mm venous
diameter, re-embolization was scheduled. At the end of the
Table 1. Inclusion and Exclusion Criteria
Inclusion criteria
Signed informed consent
Age > 18 y
Presence of chronic abdominal or pelvic pain for > 6 months
> 6 mm pelvic venous caliber measured by transvaginal US
Presence of venous reflux or communicating veins by
transvaginal Doppler US
Exclusion criteria
Diagnosed gynecologic or pelvic pathology: endometriosis,
pelvic inflammatory disease, postoperative adhesions,
adenomyosis, or leiomyoma
Glomerular filtration rate < 60 mL/min
History of contrast agent reaction
Patients not able to be followed for at least 1 y






Age, y, mean ± SD 41.0 ± 6.26 44.3 ± 8.45 .004*
Living children, median; range 2.0; 0–4 2.0; 0–4 .789†




7.0; 5–9 8.0; 5–10 .004†
Pain in orthostatic position 48 (96%) 50 (100%) .247‡
Pain in supine position 7 (14%) 6 (12%) .766§
Dyspareunia 27 (54%) 27 (54%) .999§
Dysmenorrhea 27 (54%) 36 (72%) .062§
Urinary urgency 7 (14%) 6 (12%) .766§
History
Ovarian cystic disease 22 (44%) 21 (42%) .840§
Vaginal varicosities 10 (20%) 8 (16%) .603§
Vulvar varicosities 18 (36%) 19 (38%) .836§
Lower limb varices 45 (90%) 44 (88%) .749§
Limb varices surgery 10 (20%) 10 (20%) .999§
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2017 5study, all the patients answered a quality questionnaire by
telephone, scoring their satisfaction with the procedure from
0 to 9, defined as follows: 0–1, very unsatisfied; 2–3, unsat-
isfied; 4–5, neutral; 6–7, satisfied; and 8–9, very satisfied.Transvaginal Doppler US
Maximum right pelvic venous
caliber, median; range
7.0; 5–10 7.0; 5–11 .938*
Maximum left pelvic venous
caliber, median; range
7.0; 5–10 7.0; 5–10 .392*
Ovarian vein reflux 40 (80%) 35 (70%) .248§
Waveform change in
Valsalva maneuver
25 (50%) 30 (60%) .315§
BMI ¼ body mass index; FPC ¼ fibered platinum coil; VAS ¼
visual analog scale; VP ¼ vascular plug.Cost Analysis
The differential costs were calculated by taking into account
only the price of the different devices used on each case
(FPCs, VPs, and introducer sheaths) assuming the same cost
for the rest of the procedure. Prices were estimated ac-
cording to the hospital charge list. Other costs, such as
contrast quantity, other materials, and hospital stay, were not




Normality was tested using the Kolmogorov-Smirnoff test.
Quantitative variables were expressed as mean and SD or
median and range. Qualitative data were expressed as the total
number of events and percentages. Continuous variables were
analyzed using Student t test as the parametric test and Mann-
WhitneyU test as the nonparametric test. Thec2 test andFisher
exact test were used for categorical variables. Time data were
represented in a scatterplot, and the evolution of theVAS score
over time (1, 3, 6, and 12 months) was plotted in a line chart.
All tests of significance were 2-sided, and P < .05 was
considered significant. Data were processed and analyzed us-
ing IBMSPSSVersion 21.0 (IBMCorp, Armonk, NewYork).RESULTS
As shown in Figure 1, 107 patients were assessed for
eligibility. Of the patients, 7 were excluded owing to
diagnosis of other pelvic pathology (n ¼ 2), declining to
participate (n ¼ 4), or missing the informative consultation
(n ¼ 1), and 100 patients were randomly assigned to the 2
groups. No patients were lost at 1, 3, 6, or 12 months of
follow-up, and all 100 patients were analyzed. All patients
were recruited between January 2014 and January 2015 and
followed for 12 months until February 2016.Treatment
In both groups, in 96% of the cases, embolization was suc-
cessful in almost all targeted veins (ovarian and internal iliac
veins); in 2 patients, the surgeon was unable to achieve
embolization of the right ovarian veins because of anatomic
variants. The intraoperative variables are provided inTable 3.
To achieve total occlusion of the 4 veins, 15–21 FPCs were
needed (Figs 3, 4) and 4–6 VPs were needed (Figs 5, 6)
(P < .001). Although the number of devices was lower, the
total differential cost (embolization devices and introducer
sheath, assuming the same cost for the rest of the procedure)
was significantly higher in the VP group. Total procedure
time, total fluoroscopy time, and radiation dose were
significantly lower in the VP group (Fig 7).
There were 12 minor complications, graded according to
Society of Interventional Radiology (SIR) reporting stan-
dards (20), 8 (16%) in the FPC group and 4 (8%) in the VP
group (Table 4). Major complications involved migration of
4 devices. Three coils migrated from the left internal iliac
vein to the right pulmonary arteries (n ¼ 2) or left
pulmonary artery (n ¼ 1). One VP migrated from the left
Figure 3. Final outcome of embolization procedure of all 4
targeted pelvic veins. LIIV ¼ left internal iliac vein; LOV ¼ left
ovarian vein; RIIV ¼ right internal iliac vein; ROV ¼ right ovarian
vein. Arrowheads indicate embolic devices (FPCs).
Figure 4. Contrast venography demonstrates complete occlu-
sion of the right internal iliac vein after successful embolization
procedure with FPCs.
Table 3. Intraoperative Variables
Variable FPC (n ¼ 50) VP (n ¼ 50) P
Embolization devices, median; range 18.0; 15–21 4.0; 4–7 .000*
Cost of embolization devices, V, median; range 2,915.90; 2,430.00–3,401.93 3,520.00; 3,520.00–6,160.00 .000*
Total procedure time, min, mean ± SD 44.5 ± 4.09 29.0 ± 5.95 .000†
Fluoroscopy time, min, mean ± SD 33.4 ± 4.68 19.5 ± 6.14 .000†
DAP, mGy$∙ cm2, median; range 384,957.0; 118,125.0–632,758.0 144,287.5; 879,90.0–451,817.0 .000*
Total air kerma, mGy, median; range 975.9; 233.98–2,132.40 296.0; 189.37–986.49 .000*
DAP ¼ dose area product; FPC ¼ fibered platinum coil; VP ¼ vascular plug.
*Mann-Whitney U test.
†Student t test.
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Migrations to the lung were asymptomatic and diagnosed
by chest radiograph that was performed for different
reasons (routine radiographs [n ¼ 3] and suspicion of
influenza-like illness [n ¼ 1]). The coil migrations were
discovered 3, 5, and 6 months after the procedure, and the
VP migration was discovered 3 months after the procedure.
All devices were retrieved with no consequence using right
jugular access and a 6-F vascular snare.Clinical Outcomes
Clinical success at 1-year follow-up was achieved in all 100
patients with a disappearance of symptoms before theprocedure: dyspareunia (83.3%), dysmenorrhea (88.7%),
and urinary urgency (92.8%). Subjective pain assessed with
the VAS scale showed a 90.2% improvement. The evolution
of pain was not significantly different between the 2 groups
at any of the time points, although both devices resulted in
improvement of chronic pelvic pain in almost all patients
(Fig 8). At 1-year follow-up, clinical success did not
significantly differ between the groups in regard to
improvement of pelvic symptoms or lack of pelvic pain as
self-assessed by the VAS (Table 5).
A second embolization procedure was performed in 9
patients owing to lack of improvement in chronic pelvic pain,
including 7 patients in the FPC group and 2 patients in the VP
group (P¼.095). Transvaginal Doppler ultrasound confirmed
Figure 5. Final outcome of embolization procedure of all 4
targeted pelvic veins. LIIV¼ left internal iliac vein; LOV ¼ left
ovarian vein; RIIV ¼ right internal iliac vein; ROV ¼ right ovarian
vein. Black arrows indicate embolic devices (VPs). Black
star ¼ intrauterine device; white arrow ¼ navel piercing.
Figure 6. Contrast venography demonstrates complete occlu-
sion of the left internal iliac vein after successful embolization
procedure with a VP.
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2017 7persistent or recurrent varices after embolization, which was
evident in all cases. Recurrent varices after embolization were
targeted for a new embolization procedure; 2 of the patients
were scheduled in the first month, 5 were scheduled in the first
3 months, and 2 were scheduled in the first 6 months after
clinical evaluation. After treatment, symptoms improved in
all patients. The mean satisfaction score at the end of the
study, based on the quality questionnaire conducted by tele-
phone, was 8.1 points ± 1.05 (range, 0–9). No significant
difference was found between the 2 groups (8.2 points ± 1.04
in FPC vs 7.9 points ± 1.05 in VP; P ¼ .061).Figure 7. Relationship between total fluoroscopy time (min; y
axis) and total procedure time (min; x axis) compared between
the 2 embolic devices, FPCs (black dots) and VPs (white dots).DISCUSSION
It is currently accepted that transcatheter embolization of the
pelvic veins is the least invasive and most efficacious man-
agement option for pelvic varices (21). Different treatment
methods have been proposed with divergent results (22,23),
but embolization of ovarian and pelvic veins is considered to
have the best outcome (3,5,6,24) and is recommended with a
grade 2B level of evidence according to the Society for
Vascular Surgery and the American Venous Forum (25).
However, few randomized studies are available to compare
the long-term outcome (11,25). Some authors recommend
the combined use of coils and sclerosing agents (5). Avail-
able clinical evidence and randomized studies areinsufficient to compare outcomes and recurrence using only
coils or the combined treatment. In the research group
experience, the results are similar, so the procedure was
simplified as much as possible. Some authors have pointed
out that ovarian vein embolization alone is enough to achieve
Table 4. Complications
FPC (n ¼ 50) VP (n ¼ 50) P
Minor complications
Access site hematoma 2 (4%) 2 (4%) .999*
Ovarian vein extravasation 6 (12%) 2 (4%) .232*
Major complications
Device migration 3 (6%) 1 (2%) .223*
Total 11 (22%) 5 (10%) .059†
FPC ¼ fibered platinum coil; VP ¼ vascular plug.
*Fisher exact test.
†c2 test.
Table 5. Clinical Outcomes at End of 1-Year Follow-up
Variable FPC (n ¼ 50) VP (n ¼ 50) P*
Disappearance of
dyspareunia
24/27 (88.9%) 21/27 (77.8%) .370
Disappearance of
dysmenorrhea
24/27 (88.8%) 31/35 (88.6) .999
Disappearance of
urinary urgency
6/7 (85.7%) 6/6 (100%) .999
VAS score improvement 47/49 (95.9%) 48/50 (96%) .999
FPC ¼ fibered platinum coil; VAS ¼ visual analog scale;
VP ¼ vascular plug.
*Fisher exact test.
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ported success with embolization of the left ovarian vein
alone (6). Ratnam et al (26) recommended embolization only
of veins with reflux demonstrated by venography. Larger
series demonstrated results in 85%–96% of patients by per-
forming bilateral ovarian and internal iliac vein emboliza-
tion. The main limitation of these studies is a relatively short
follow-up time (27). The present randomized controlled trial
was performed to assess whether venous embolization for
PCS with VPs could reduce the number of embolic devices
and procedure time without significant differences in the
clinical success or complication rate compared with FPCs.
The Society for Vascular Surgery and the American Venous
Forum recommend coil embolization, plugs, or transcatheter
sclerotherapy as standard treatments, with a grade 2B level of
evidence (17) owing to limited evidence, over othermedical or
surgically invasive treatments (18). In this study, bothFigure 8. Evolution of pain assessed with VAS over time
(before procedure and after 12 months of follow-up) for both
groups, represented as medians and error bars with 95% confi-
dence interval. Black line and black error bars represent FPCs.
White line and white error bars represent VPs.treatments had high rates of technical and clinical success, as
shown in other noncomparative studies (3,4,6,7,16,17). There
were no differences in the efficacy of the devices. Complete
occlusion confirmed by venography was achieved with both
VPs and FPCs, but the number of coils needed was signifi-
cantly greater than the number of plugs (a mean of 4–5 FPCs
per 1 VP), as reported in other studies (5–12 coils per 1 VP)
(13,14,28,29). Previous studies also found a significant
decrease in procedure and fluoroscopy times in the VP group
and a decrease in radiation dose, although the difference was
significant in the present study but not in previous ones
(14,29). This decrease in procedure timemaybe causedmainly
by the need to verify vessel occlusion between groups of coils
in the FPC group. This is especially relevant in this specific
pathology, as it reduces the radiation dose in the pelvic area of
young fertile women as well as the exposure of the operator.
A disadvantage of VPs is that the largest size must be
used to achieve total occlusion of these veins, which usually
have a very large diameter. These sizes (Amplatzer Vascular
Plug II 14–22 mm in diameter) require a minimum catheter
size of 8–9 F, whereas large coils can usually be delivered
with a 5-F catheter. Some authors have reported a longer
embolization time for occlusion with a single VP—from 3–5
minutes to > 15–20 minutes (12,29). All these procedures
have been performed in high-flow arteries (splenic, iliac,
gastroduodenal), and no difference was observed in this
study in the embolization time between devices in the
venous territory. Nevertheless, when considering the num-
ber of coils needed for total occlusion, most authors (13,14)
have reported a significantly lower occlusion time for VPs.
All migrations resulted from internal iliac veins in which
embolization had been achieved and occurred 3–6 months
after the procedure. Device migrations might be related to
the actual oversize diameter percentage, 15%–20% in in-
ternal iliac veins. VP manufacturers suggest an oversizing of
30%–50% with respect to the target vessel diameter (30).
Despite the low oversize estimation, only 2% (1 of 50) of
patients presented with device migration in the VP group
and 6% (3/50) of patients presented with device migration in
the FPC group without statistical significance. The pelvic
venous plexus has different physiologic and histologic
characteristics compared with arteries. Veins have thinner
walls with large lumen diameters and the lack of elastic
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2017 9membrane in the tunica media, resulting in low-pressure,
low-resistance vessels with high capacitance compared
with arteries (31). These characteristics can predispose for
device migration because of a higher passive compliance as
well as an opposite blood flow when performing an embo-
lization procedure in pelvic veins compared with an arterial
embolization. Other authors have published similar results
regarding coil migration: Venbrux et al (3), 3.6% of patients
(2 of 56); Laborda et al (7), 1.9% of patients (4 of 202); Kim
et al (5), 1.5% of patients (2 of 127); and Kwon et al (6), 3%
of patients (2 of 67) as well as others (4).
Among the main limitations of the present study are the
significant differences between groups in age and VAS score
before treatment, both of which were slightly higher in the VP
group despite randomization. However, these differences did
not have clinical repercussions (severe pain scores on the VAS
were 7–9). Another limitation is that clinical success, referring
to pain and discomfort, is difficult to measure objectively. A
subjective scale, such as the VAS, can be influenced by other
concomitant disorders and environmental or psychological
conditions. Cost calculation is another limitation of the study.
Prices for these devices differ between countries and even
between regions of the same country. In this study, VPs were
significantly more expensive, but other studies with very
similar data demonstrated a significant cost savings of between
$410 and $1,375 when using VPs in gastroduodenal and in-
ternal iliac arteries (13,29). The total cost was not calculated,
only the cost of the embolization device. The total material,
contrast media, hospital stay, operating time, and complication
costs (eg,material for device retrieval)were not included in the
analysis. As a practical consideration and taking reimburse-
ment into account, each hospital should interpret and use these
data for application in their local environment.
In conclusion, venous embolization for the treatment of
PCS is equally safe and effective with FPCs or VPs, with a
significant improvement in pelvic symptoms for PCS. Fewer
VPs were needed to achieve total occlusion with the same
clinical outcome as FPCs, and the procedure and fluoros-
copy times and radiation dose were also reduced.REFERENCES
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